Tri-complex inhibitors (TCIs) are molecular glues that bind to active GTP-bound RAS and recruit the intracellular chaperone cyclophilin A (CYPA) to generate a synthetic inhibitory complex that blocks ...
At the moment, RevMed remains keenly focused on its mission to bring daraxonrasib to the masses and continue developing new medicines that target RAS. (Darren Incorvaia) This year’s meeting of the ...
The missile attack that Iran launched against Qatar in mid-March sent plumes of smoke rising from the largest natural-gas production facility in the world. It destroyed sections of a plant that ...
An investigational oral drug that targets RAS, the dominant oncogenic driver in pancreatic cancer, nearly doubled overall survival compared with common second-line chemotherapy regimens in patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results